Therapeutic antibody development company Patrys Ltd (ASX:PAB) has been granted two patents by the US Patent and Trademark Organisation (US PTO) that deliver further intellectual property protection for Patrys’ deoxymab antibody technology.
Treating cancer
The first patent covers the composition of matter for Patrys’ lead clinical deoxymab antibodies PAT-DX1 and PAT-DX3, while the second US patent covers use of Patrys’ novel deoxymab technology, including both PAT-DX1 and PAT-DX3, conjugated to a nanocarrier for the treatment of cancer.
The two patents provide protection for the intellectual property and claims that they encompass until 2039.
US patent number: 11,613,590, 'Binding proteins 1', provides coverage until September 2039, while US patent number: 11,590,242, 'Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors' provides coverage until January 2039.
Robust intellectual property protection
The ‘composition of matter’ patent provides robust intellectual property protection around the deoxymabs themselves, including variants thereof, as well as their use for therapeutic applications.
This patent, co-filed with Yale University, is the first US patent to be granted specifically for PAT-DX1 and PAT-DX3, the humanised forms of the original 3E10 antibody.
The second patent covers the combination of deoxymabs with nanocarriers that simultaneously cause DNA damage or inhibit the repair of damaged DNA to potentially provide a powerful new approach for treating cancer.
There are now five granted patents covering the use of conjugated deoxymabs that provide opportunities for both internal development programs and partnering opportunities for Patrys.
“The granting of these two patents provides Patrys with robust intellectual property covering both the humanised form of the antibody and its conjugated form,” Patrys CEO and managing director Dr James Campbell said.
Expanding patent estate
“The company has multiple patents granted in the United States and other major jurisdictions which cover a broad range of applications for using deoxymabs to treat cancer and deliver therapeutic payloads.
“As well as expanding Patrys’ patent estate, these new patents provide the intellectual property coverage to enable the company or potential partners or licensees to invest in development programs for these applications.”
There are now six granted patents covering the unconjugated form of deoxymab 3E10 (and derivatives) in Europe, Japan and China, as well as three granted in the US.
In addition, the company has five patents covering nanoparticle conjugation granted in Australia, Canada, China, India and the US.
Patrys and its clinical partner Yale have filed more than 44 patent applications across 13 different patent families in major jurisdictions, giving the company a ‘significant patent estate’ covering the use of its deoxymab platform for the treatment of cancer.